Faculty Profiles

Wilfrido, Mojica
Mojica, Wilfrido, MDAssociate Professor
Email: mojica@buffalo.edu
Phone: (716) 859-2140

Specialty/Research Focus:
Anatomic Pathology; Clinical Pathology; Molecular Genetic Pathology - Clinical Biochemical; Surgical Pathology

Research Summary:
Professional Summary: As a pathologist, I help cover the clinical duties for the Kaleida Health system’s anatomical pathologist needs at the Buffalo General Medical Center, Suburban Hospital and DeGraff Hospital. I am Board certified in Anatomic and Clinical Pathology with an interest in oncologic pathology and approaches related to precision medicine. The majority of my time is allocated for clinical service work, which includes general surgical pathology, some clinical pathology coverage, and the teaching of pathology residents. Additional clinical duties include overseeing the laboratory’s immunohistochemistry section and involvement in the build-up of the CTRC’s biobank. For resident education, one major emphasis currently being undertaken is the deciphering of the technical and bioinformatic bridges that separate pathologists from those involved in the field of genomic sequencing. Dedicated research time has allowed me to be involved in investigations centered on improvements in sample procurement and biomarker studies for antibody-drug conjugate (ADC) characterization. Current work on the former is centered on the development of an automated prototype for the processing of cells recovered from washed core needle biopsies, but with utility for any ‘wet’ type biopsy or sample (e.g., cytology specimens). This prototype is intended to enable unfixed cells to travel through a microfluidic platform that will allow for their quantitative evaluation and assessment of their cytologic features for diagnostic purposes, and their recovery for downstream molecular studies. Because of their unfixed nature, we are assessing the utility of the DNA extracted from these cells for long read sequencing technologies, believing these devices will ultimately replace both multi-panel, next generation tests and FISH assays for the elucidation of molecular abnormalities at both the single nucleotide and structural variation level. This approach will preserve the original core needle biopsy tissue for further tissue-based testing that requires morphologic evaluation, in particular, the profiling of tumor tissue to guide treatment with the aforementioned ADC currently being tested in clinical trials. The underlying effort is to maximize the amount of informative data derived from diminutive biospecimens and prevent the current problems associated with tissue exhaustion.